Verdiperstat ( DrugBank: Verdiperstat )


3 diseases
告示番号疾患名(ページ内リンク)臨床試験数
2筋萎縮性側索硬化症1
17多系統萎縮症7
127前頭側頭葉変性症1

2. 筋萎縮性側索硬化症


臨床試験数 : 645 薬物数 : 589 - (DrugBank : 163) / 標的遺伝子数 : 150 - 標的パスウェイ数 : 225
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04297683
(ClinicalTrials.gov)
July 14, 20203/3/2020HEALEY ALS Platform Trial - Master ProtocolHEALEY ALS Platform TrialAmyotrophic Lateral SclerosisDrug: Zilucoplan;Drug: Verdiperstat;Drug: CNM-Au8;Drug: Pridopidine;Drug: SLS-005 TrehaloseMerit E. Cudkowicz, MDMassachusetts General HospitalRecruiting18 YearsN/AAll800Phase 2/Phase 3United States

17. 多系統萎縮症


臨床試験数 : 119 薬物数 : 138 - (DrugBank : 44) / 標的遺伝子数 : 59 - 標的パスウェイ数 : 111
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT05086094
(ClinicalTrials.gov)
October 14, 20218/10/2021Expanded Access Protocol of Verdiperstat in Patients With Multiple System Atrophy (MSA)Intermediate-Size Patient Population Expanded Access Protocol of Verdiperstat in Patients With Multiple System Atrophy (MSA)Multiple System Atrophy (MSA)Drug: BHV3241, verdiperstatBiohaven Pharmaceuticals, Inc.NULLNo longer availableN/AN/AAllUnited States
2EUCTR2019-001100-38-IT
(EUCTR)
19/02/202026/01/2021A study to assess whether a drug called BHV-3241 works and is safe to use in people with Multiple System Atrophy (M-STAR Study)Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of BHV-3241 in Subjects with Multiple System Atrophy (M-STAR Study) - M-STAR Study Multiple System Atrophy
MedDRA version: 21.1;Level: PT;Classification code 10064060;Term: Multiple system atrophy;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: BHV-3241
Product Code: [/]
INN or Proposed INN: Verdiperstat
Biohaven Pharmaceuticals, Inc.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
252Phase 3France;United States;Austria;Germany;United Kingdom;China;Italy
3EUCTR2019-001100-38-DE
(EUCTR)
07/01/202007/10/2019A study to assess whether a drug called BHV-3241 works and is safe to use in people with Multiple System Atrophy (M-STAR Study)Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of BHV-3241 in Subjects with Multiple System Atrophy (M-STAR Study) Multiple System Atrophy
MedDRA version: 21.1;Level: PT;Classification code 10064060;Term: Multiple system atrophy;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: BHV-3241
INN or Proposed INN: Verdiperstat
Biohaven Pharmaceuticals, IncNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
422Phase 3United States;France;Austria;Germany;United Kingdom;Italy;China
4EUCTR2019-001100-38-AT
(EUCTR)
20/12/201929/10/2019A study to assess whether a drug called BHV-3241 works and is safe to use in people with Multiple System Atrophy (M-STAR Study)Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of BHV-3241 in Subjects with Multiple System Atrophy (M-STAR Study) Multiple System Atrophy
MedDRA version: 21.1;Level: PT;Classification code 10064060;Term: Multiple system atrophy;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: BHV-3241
INN or Proposed INN: Verdiperstat
Biohaven Pharmaceuticals, IncNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
422Phase 3United States;France;Austria;Germany;United Kingdom;Italy;China
5EUCTR2019-001100-38-FR
(EUCTR)
13/12/201903/10/2019A study to assess whether a drug called BHV-3241 works and is safe to use in people with Multiple System Atrophy(M-STAR Study)Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of BHV-3241 in Subjects with Multiple System Atrophy (M-STAR Study) Multiple System Atrophy
MedDRA version: 21.1;Level: PT;Classification code 10064060;Term: Multiple system atrophy;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: BHV-3241
INN or Proposed INN: Verdiperstat
Biohaven Pharmaceuticals, IncNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
252Phase 3Austria;United States;Italy;United Kingdom;France;Germany
6EUCTR2019-001100-38-GB
(EUCTR)
06/12/201911/10/2019A study to assess whether a drug called BHV-3241 works and is safe to use in people with Multiple System Atrophy(M-STAR Study)Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of BHV-3241 in Subjects with Multiple System Atrophy (M-STAR Study) Multiple System Atrophy
MedDRA version: 21.1;Level: PT;Classification code 10064060;Term: Multiple system atrophy;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: BHV-3241
INN or Proposed INN: Verdiperstat
Biohaven Pharmaceuticals, IncNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
422Phase 3United States;France;Austria;Germany;Italy;United Kingdom
7NCT03952806
(ClinicalTrials.gov)
July 29, 201915/5/2019Study of BHV-3241 in Subjects With Multiple System AtrophyA Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Study to Evaluate the Efficacy and Safety of BHV-3241 in Subjects With Multiple System Atrophy (M-STAR Study)Multiple System AtrophyDrug: Verdiperstat;Drug: PlaceboBiohaven Pharmaceuticals, Inc.NULLCompleted40 Years80 YearsAll336Phase 3United States;Austria;France;Germany;Italy;United Kingdom

127. 前頭側頭葉変性症


臨床試験数 : 90 薬物数 : 87 - (DrugBank : 30) / 標的遺伝子数 : 39 - 標的パスウェイ数 : 88
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT05184569
(ClinicalTrials.gov)
April 14, 202217/12/2021Veri-T: A Trial of Verdiperstat in Patients With svPPA Due to TDP-43 PathologyPhase 1, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy Study of Oral Verdiperstat (BHV-3241) in Patients With Semantic Variant Primary Progressive Aphasia (svPPA) Due to TDP-43 PathologySemantic DementiaDrug: VerdiperstatPeter Ljubenkov, MDNational Institutes of Health (NIH);Alzheimer's Association;National Institute on Aging (NIA)Recruiting18 Years85 YearsAll64Phase 1United States